Bremelanotide, also known as PT-141, is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a small peptide hormone that acts on melanocortin receptors in the brain and body.
Bremelanotide is currently approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved drug for the treatment of HSDD in women.
Other names for bremelanotide
Bremelanotide is also known as:
- PT-141
- Vyleesi (brand name)
- Melanotan II analogue
- Cyclic heptapeptide lactam analogue of α-MSH
History of bremelanotide
Bremelanotide was originally developed as a sunless tanning agent, but it was later discovered to have arousing effects. Bremelanotide is now FDA-approved for the treatment of HSDD in women, and it is being investigated for the treatment of other conditions.
How does bremelanotide work?
Bremelanotide works by stimulating melanocortin receptors in the brain. These receptors are involved in a variety of physiological processes, including sexual function.
When bremelanotide binds to melanocortin receptors in the brain, it increases the release of dopamine and nitric oxide. Dopamine is a neurotransmitter that plays a key role in sexual desire, arousal, and pleasure. Nitric oxide is a vasodilator that increases blood flow to the genitals.
Bremelanotide also stimulates the release of other hormones that play a role in sexual function, such as testosterone and oxytocin.
How is bremelanotide used?
Bremelanotide is administered as a subcutaneous injection. It is typically injected into the abdomen or thigh.
Bremelanotide is taken on an as-needed basis, 45 minutes before sexual activity.
Side effects of bremelanotide
Bremelanotide is generally well-tolerated, but some people may experience side effects such as:
- Flushing
- Nausea
- Headache
- Dizziness
- Hypotension
- Injection site reactions
In rare cases, bremelanotide can cause more serious side effects, such as:
- Seizures
- Allergic reactions
- Liver toxicity
Bremelanotide is not recommended for people with certain medical conditions, such as:
- Cardiovascular disease
- Liver disease
- Kidney disease
- Seizure disorders
- Mental health disorders
Bremelanotide is a promising new drug for the treatment of sexual dysfunction in women. It is the first and only FDA-approved drug for the treatment of HSDD in women, and it is being investigated for the treatment of other conditions.
Bremelanotide is generally well-tolerated, but some people may experience side effects. It is important to talk to your doctor before taking bremelanotide to discuss the risks and benefits.
